These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37941520)

  • 1. Mechanisms of carboplatin- and paclitaxel-dependent induction of premature senescence and pro-cancerogenic conversion of normal peritoneal mesothelium and fibroblasts.
    Rutecki S; Pakuła-Iwańska M; Leśniewska-Bocianowska A; Matuszewska J; Rychlewski D; Uruski P; Stryczyński Ł; Naumowicz E; Szubert S; Tykarski A; Mikuła-Pietrasik J; Książek K
    J Pathol; 2024 Feb; 262(2):198-211. PubMed ID: 37941520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts.
    Uruski P; Mikuła-Pietrasik J; Pakuła M; Budkiewicz S; Drzewiecki M; Gaiday AN; Wierzowiecka M; Naumowicz E; Moszyński R; Tykarski A; Książek K
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro.
    Uruski P; Sepetowska A; Konieczna C; Pakuła M; Wyrwa M; Tussupkaliyev A; Tykarski A; Mikuła-Pietrasik J; Książek K
    Cell Mol Biol Lett; 2021 Oct; 26(1):44. PubMed ID: 34674640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senescence-related deterioration of intercellular junctions in the peritoneal mesothelium promotes the transmesothelial invasion of ovarian cancer cells.
    Pakuła M; Witucka A; Uruski P; Radziemski A; Moszyński R; Szpurek D; Maksin K; Woźniak A; Sajdak S; Tykarski A; Mikuła-Pietrasik J; Książek K
    Sci Rep; 2019 May; 9(1):7587. PubMed ID: 31110245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis.
    Rutecki S; Szulc P; Pakuła M; Uruski P; Radziemski A; Naumowicz E; Moszyński R; Tykarski A; Mikuła-Pietrasik J; Książek K
    J Ovarian Res; 2022 Jul; 15(1):87. PubMed ID: 35883110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
    Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
    Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress contributes to hepatocyte growth factor-dependent pro-senescence activity of ovarian cancer cells.
    Mikuła-Pietrasik J; Uruski P; Pakuła M; Maksin K; Szubert S; Woźniak A; Naumowicz E; Szpurek D; Tykarski A; Książek K
    Free Radic Biol Med; 2017 Sep; 110():270-279. PubMed ID: 28652056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Carnosine Prevents the Pro-cancerogenic Activity of Senescent Peritoneal Mesothelium Towards Ovarian Cancer Cells.
    Mikuła-Pietrasik J; Książek K
    Anticancer Res; 2016 Feb; 36(2):665-71. PubMed ID: 26851022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
    Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
    Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
    Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway.
    Yasui H; Kajiyama H; Tamauchi S; Suzuki S; Peng Y; Yoshikawa N; Sugiyama M; Nakamura K; Kikkawa F
    Clin Exp Metastasis; 2020 Feb; 37(1):145-158. PubMed ID: 31541326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer.
    Wang L; Xiong B; Lu W; Cheng Y; Zhu J; Ai G; Zhang X; Liu X; Cheng Z
    Biomed Pharmacother; 2024 May; 174():116474. PubMed ID: 38518604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
    Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
    Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
    Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
    Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
    Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo.
    Mikuła-Pietrasik J; Sosińska P; Naumowicz E; Maksin K; Piotrowska H; Woźniak A; Szpurek D; Książek K
    Clin Exp Metastasis; 2016 Jan; 33(1):15-27. PubMed ID: 26433963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
    Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
    Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Sereni MI; Baldelli E; Gambara G; Ravaggi A; Hodge KA; Alberts DS; Guillen-Rodriguez JM; Dong T; Memo M; Odicino F; Angioli R; Liotta LA; Pecorelli SL; Petricoin EF; Pierobon M
    Br J Cancer; 2017 Aug; 117(4):494-502. PubMed ID: 28664915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.